End-of-day quote
NSE India S.E.
06:00:00 2024-05-30 pm EDT
|
5-day change
|
1st Jan Change
|
1,907
INR
|
-0.71%
|
|
-3.25%
|
+13.62%
|
Fiscal Period: März |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
65,032
|
114,563
|
104,174
|
63,926
|
97,675
|
-
|
-
|
Enterprise Value (EV)
1 |
62,802
|
110,283
|
104,952
|
63,654
|
88,295
|
95,476
|
93,551
|
P/E ratio
|
50.9
x
|
62.6
x
|
48.9
x
|
44.9
x
|
69.3
x
|
54.7
x
|
43.1
x
|
Yield
|
0.62%
|
0.36%
|
0.39%
|
0.64%
|
0.51%
|
0.57%
|
0.72%
|
Capitalization / Revenue
|
7.59
x
|
11.5
x
|
8.48
x
|
5.57
x
|
7.31
x
|
7.18
x
|
6.35
x
|
EV / Revenue
|
7.33
x
|
11.1
x
|
8.54
x
|
5.54
x
|
7.31
x
|
7.02
x
|
6.08
x
|
EV / EBITDA
|
27
x
|
38.6
x
|
30.6
x
|
22.1
x
|
31.2
x
|
27.7
x
|
23.1
x
|
EV / FCF
|
33.8
x
|
49.9
x
|
47.1
x
|
32.7
x
|
55.2
x
|
41.5
x
|
31.9
x
|
FCF Yield
|
2.96%
|
2%
|
2.12%
|
3.05%
|
1.81%
|
2.41%
|
3.14%
|
Price to Book
|
12.4
x
|
16.2
x
|
11.8
x
|
6.47
x
|
9.1
x
|
8.08
x
|
7.19
x
|
Nbr of stocks (in thousands)
|
50,631
|
51,117
|
51,172
|
51,211
|
51,229
|
-
|
-
|
Reference price
2 |
1,284
|
2,241
|
2,036
|
1,248
|
1,907
|
1,907
|
1,907
|
Announcement Date
|
5/29/20
|
5/27/21
|
5/24/22
|
5/16/23
|
5/21/24
|
-
|
-
|
Fiscal Period: März |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
7,694
|
8,564
|
9,980
|
12,283
|
11,482
|
12,077
|
13,602
|
15,394
|
EBITDA
1 |
2,086
|
2,328
|
2,860
|
3,428
|
2,883
|
2,826
|
3,442
|
4,050
|
EBIT
1 |
-
|
1,685
|
2,401
|
2,796
|
1,991
|
1,881
|
2,417
|
2,980
|
Operating Margin
|
-
|
19.68%
|
24.05%
|
22.76%
|
17.34%
|
15.58%
|
17.77%
|
19.36%
|
Earnings before Tax (EBT)
1 |
-
|
1,687
|
2,443
|
2,934
|
1,875
|
1,747
|
2,392
|
3,049
|
Net income
1 |
-
|
1,273
|
1,831
|
2,142
|
1,429
|
1,278
|
1,771
|
2,266
|
Net margin
|
-
|
14.87%
|
18.35%
|
17.44%
|
12.44%
|
10.58%
|
13.02%
|
14.72%
|
EPS
2 |
24.02
|
25.25
|
35.79
|
41.66
|
27.81
|
24.87
|
34.86
|
44.20
|
Free Cash Flow
1 |
-
|
1,858
|
2,208
|
2,226
|
1,945
|
1,749
|
2,303
|
2,935
|
FCF margin
|
-
|
21.7%
|
22.13%
|
18.12%
|
16.94%
|
14.7%
|
16.93%
|
19.06%
|
FCF Conversion (EBITDA)
|
-
|
79.81%
|
77.22%
|
64.94%
|
67.45%
|
61.77%
|
66.91%
|
72.46%
|
FCF Conversion (Net income)
|
-
|
145.94%
|
120.62%
|
103.94%
|
136.1%
|
130.95%
|
130.06%
|
129.54%
|
Dividend per Share
2 |
13.26
|
8.000
|
8.000
|
8.000
|
8.000
|
9.753
|
10.83
|
13.73
|
Announcement Date
|
5/13/19
|
5/29/20
|
5/27/21
|
5/24/22
|
5/16/23
|
5/21/24
|
-
|
-
|
Fiscal Period: March |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
2,748
|
2,917
|
3,268
|
3,026
|
2,931
|
3,059
|
2,799
|
3,003
|
2,855
|
2,825
|
2,771
|
3,059
|
2,932
|
3,052
|
3,129
|
EBITDA
1 |
866.4
|
963.9
|
1,024
|
902.4
|
753.3
|
748.5
|
684.9
|
790.3
|
704.9
|
702.9
|
629.4
|
769.6
|
709.6
|
753.6
|
741
|
EBIT
1 |
756.7
|
823.1
|
890.6
|
752
|
584.4
|
568.6
|
473.2
|
574.5
|
474.6
|
468.5
|
421.2
|
545.2
|
489.9
|
509.2
|
491
|
Operating Margin
|
27.54%
|
28.21%
|
27.26%
|
24.85%
|
19.94%
|
18.59%
|
16.91%
|
19.13%
|
16.63%
|
16.58%
|
15.2%
|
17.82%
|
16.71%
|
16.68%
|
15.7%
|
Earnings before Tax (EBT)
1 |
777.7
|
816.5
|
1,031
|
777.1
|
560.9
|
564.7
|
428.3
|
548
|
479.7
|
-
|
391.9
|
511.3
|
451.5
|
510.2
|
461
|
Net income
1 |
585.7
|
613.5
|
748.9
|
582.7
|
410.4
|
399.9
|
334
|
403.3
|
358
|
333.6
|
289.8
|
390.8
|
336.4
|
382
|
345
|
Net margin
|
21.32%
|
21.03%
|
22.92%
|
19.25%
|
14%
|
13.07%
|
11.93%
|
13.43%
|
12.54%
|
11.81%
|
10.46%
|
12.78%
|
11.47%
|
12.51%
|
11.03%
|
EPS
2 |
11.46
|
11.99
|
14.58
|
11.34
|
7.980
|
7.780
|
6.490
|
7.850
|
6.970
|
6.490
|
5.610
|
7.592
|
6.872
|
7.207
|
7.310
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/10/21
|
5/27/21
|
8/6/21
|
11/10/21
|
2/11/22
|
5/24/22
|
8/10/22
|
11/8/22
|
2/10/23
|
5/16/23
|
8/2/23
|
-
|
-
|
-
|
-
|
Fiscal Period: March |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
779
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
2,230
|
4,280
|
-
|
272
|
1,076
|
2,199
|
4,124
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
0.2271
x
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
1,858
|
2,208
|
2,226
|
1,945
|
1,749
|
2,303
|
2,935
|
ROE (net income / shareholders' equity)
|
-
|
31%
|
29.8%
|
26.9%
|
15.2%
|
12.8%
|
15.3%
|
17.8%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
20.8%
|
16.9%
|
9.43%
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
8,783
|
12,674
|
15,160
|
-
|
-
|
-
|
Book Value Per Share
2 |
-
|
103.0
|
138.0
|
173.0
|
193.0
|
209.0
|
236.0
|
265.0
|
Cash Flow per Share
2 |
18.00
|
-
|
48.70
|
49.30
|
48.10
|
45.60
|
58.20
|
65.20
|
Capex
1 |
196
|
292
|
282
|
307
|
526
|
498
|
506
|
461
|
Capex / Sales
|
2.54%
|
3.41%
|
2.82%
|
2.5%
|
4.58%
|
4.18%
|
3.72%
|
2.99%
|
Announcement Date
|
5/13/19
|
5/29/20
|
5/27/21
|
5/24/22
|
5/16/23
|
5/21/24
|
-
|
-
|
Last Close Price
1,907
INR Average target price
1,841
INR Spread / Average Target -3.44% Consensus |
1st Jan change
|
Capi.
|
---|
| +13.62% | 1.17B | | -24.66% | 7.76B | | +68.65% | 4.33B | | -3.50% | 2.64B | | +3.62% | 2.63B | | -46.17% | 2.16B | | -15.27% | 1.75B | | -22.12% | 1.46B | | -43.81% | 1.14B | | +19.34% | 999M |
Medical & Diagnostic Laboratories
|